Recor Medical's Commitment to Hypertension Management
Recor Medical, Inc. has made a significant impact in the field of hypertension treatment with its innovative Paradise Ultrasound Renal Denervation (uRDN) System. This technology is designed to offer advanced solutions to patients suffering from resistant or uncontrolled hypertension. Recently, the American Heart Association (AHA) and American College of Cardiology (ACC) recognized the importance of renal denervation as a valuable treatment option in their updated guidelines, marking a progressive step forward in how hypertension is understood and managed.
Understanding the AHA and ACC Guidelines
In their updated guidelines, the AHA and ACC emphasize renal denervation (RDN) as a therapeutic avenue for patients who find it challenging to manage their high blood pressure with standard medications. This acknowledgment is pivotal, merging the latest research data with real-world applications, thereby guiding healthcare professionals in their treatment strategies.
Clinical Validation and Safety of RDN
The inclusion of RDN in these guidelines is not arbitrary; it stems from thorough evaluations of randomized and sham-controlled clinical trials that span diverse patient populations. These studies confirm RDN's role in hypertension management, giving healthcare providers a solid basis for incorporating this method into their clinical practice.
Reactions from Recor Medical Leadership
Lara Barghout, the President and CEO of Recor, expressed her enthusiasm regarding the guidelines. "The recognition from the AHA and ACC fortifies our mission to support cardiovascular health through innovative therapies. Our RADIANCE Global Program lays the groundwork for integrating RDN into everyday care for patients with challenging hypertension," she stated. The program has yielded substantial clinical evidence regarding the effectiveness and safety of the Paradise uRDN System.
About the Paradise uRDN System
The Paradise uRDN System stands out as the pioneering FDA-approved technology utilizing ultrasound to address hypertension. Its design focuses on reducing blood pressure by effectively disrupting overactive nerve pathways around the renal arteries. Providing ultrasound energy in a controlled manner ensures patient safety, with the HydroCooling™ system protecting the renal artery wall during treatment.
Results from the RADIANCE Global Program
Recor has actively championed the development of the Paradise system since 2009. The company’s commitment to research is evidenced by the success of three major trials: RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO. Over 500 patients participated in these studies, all achieving their primary efficacy endpoints without compromising safety.
Long-term Studies for Continuous Improvement
In a bid to build on its achievements, Recor launched the U.S. Global Paradise System (GPS) Post-Approval Study, which aims to gather extensive real-world evidence, enrolling 1,000 patients with uncontrolled hypertension. These initiatives reflect Recor's dedication to advancing hypertension management practices continually.
Transforming Hypertension Treatment Worldwide
Headquartered in Palo Alto, California, Recor Medical is a subsidiary of Otsuka Medical Devices Co., Ltd., focused on revolutionizing hypertension treatment. The Paradise uRDN system is FDA-approved and CE marked, facilitating its distribution in markets aligned with regulatory standards. By providing clinicians with advanced tools and patients with innovative treatment options, Recor Medical is set to make waves in cardiovascular health.
Contact Information
For general inquiries, you can reach out to Media Contact Lisa Owens at The Mullings Group. Interested parties can contact her via email at lowens@mullingsgroup.com or call +1-210-601-6647 for more details.
Frequently Asked Questions
What is the Paradise Ultrasound Renal Denervation System?
The Paradise uRDN System is a cutting-edge technology designed to reduce blood pressure by targeting overactive nerves around the renal arteries using ultrasound.
Why is the AHA and ACC's recognition of RDN important?
This recognition integrates the latest research and clinical findings, solidifying RDN's role as a viable option in hypertension management.
How does the Paradise uRDN System work?
The system delivers ultrasound energy in precise doses to disrupt nerve signals that contribute to high blood pressure, helping patients achieve better control.
What clinical trials support the effectiveness of the Paradise system?
Three major trials, including RADIANCE II and RADIANCE-HTN TRIO, demonstrate its efficacy and safety in managing hypertension in a variety of patient populations.
How can patients learn more about the Paradise system?
Patients interested in learning more about the Paradise system can visit Recor Medical's official website for comprehensive information and resources.
